This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Does CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for CorMedix (CRMD) points to a 135.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for CorMedix (CRMD) points to a 146.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
How Much Upside is Left in CorMedix (CRMD)? Wall Street Analysts Think 198.21%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 21.74% and 84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of -25% and 9.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.20% and 33.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CorMedix (CRMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 10% and 1.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Stock Jumps 14.8%: Will It Continue to Soar?
by Zacks Equity Research
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Puma Biotech (PBYI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 190.91% and 16.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -20.29% and 14.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of -22.22% and 280.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in CorMedix (CRMD)
by Zacks Equity Research
CorMedix (CRMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CorMedix (CRMD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 33.33% and -89.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CorMedix (CRMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of -11.11% and 46.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 17.39% and -11.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?